Sanofi announced it will implement a new reporting structure for employees of Genzyme, which it acquired in April for $20.1 billion. Sanofi CEO Chris Viehbacher had previously indicated that Genzyme would function as a standalone biotechnology company within the French drugmaker.

In an employee bulletin, Sanofi said the Genzyme unit will be downsized to include only its personalised genetic health and multiple sclerosis operations and its oncology, biosurgery and renal operations will be integrated into Sanofi businesses.

 The drugmaker declined to say if the reporting changes would result in layoffs and no job losses have been reported in connection with the restructuring at this time.

Sanofi also indicated that Viehbacher will continue to serve as acting Genzyme CEO through September, after which a new CEO will be named.
 

• 
•